QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Aditxt, Inc. ("Aditxt" or "the Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, develo...

Core News & Articles

As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Bioscie...

Core News & Articles

Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious diseas...

 whats-going-on-with-aditxt-shares-wednesday

Aditxt and Evofem amended and restated their merger agreement.

Core News & Articles

This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success...

 evofem-biosciences-announces-issuance-of-us-patent-no-11992472-covering-composition-and-methods-for-contraception-with-phexxi-vaginal-gel

- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio --- Newly issued patent...

 aditxt-announces-pricing-of-42m-private-placement-priced-at-the-market-under-nasdaq-rules

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a company dedicated to discovering, developing, and dep...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION